MarketBeat
13 Sept 2026, 07:02 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
5 claims · each scored for market impact
GSK has implemented a change program targeting nearly £1.9 billion in savings, mostly for reinvestment into its R&D pipeline. — Significant cost efficiency paired with increased R&D investment typically drives long-term valuation growth in pharma.
+0.60GSK expects margins to remain stable or improve during the 2028-2030 period despite the patent expiration of the HIV drug dolutegravir. — Mitigates the 'patent cliff' risk, reducing the potential for a sharp earnings drop in the late 2020s.
+0.50The company has doubled its Phase III starts this year from 10 to 20, spanning seven assets and 18 indications. — A significantly expanded late-stage pipeline increases the probability of new revenue streams and product launches.
+0.40Continue reading
5 related stories
Search tags
GSK is developing longer-acting HIV therapies, including a four-month regimen expected to launch in 2028 and a six-month option. — Product evolution into long-acting injectables protects market share and addresses clinic capacity constraints.
+0.30The shingles vaccine SHINGRIX has reached 45% U.S. penetration with an expected annual increase of 2-4 percentage points. — Provides a predictable, growing revenue floor and potential for further international expansion.
+0.20Which stocks this story touches
[gsk_to_jnj] GSK makes payments to Janssen (a J&J subsidiary) for rilpivirine.
[mutual] GSK has established collaborations with Hengrui in respiratory medicine.
[mutual] GSK has established collaborations with Hansoh in oncology.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
1h ago
